SG11202112980TA - Targeted protein degradation of parp14 for use in therapy - Google Patents

Targeted protein degradation of parp14 for use in therapy

Info

Publication number
SG11202112980TA
SG11202112980TA SG11202112980TA SG11202112980TA SG11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA
Authority
SG
Singapore
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
SG11202112980TA
Other languages
English (en)
Inventor
Laurie B Schenkel
Melissa Marie Vasbinder
Kevin Wayne Kuntz
Kerren Kalai Swinger
Timothy J N Wigle
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of SG11202112980TA publication Critical patent/SG11202112980TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202112980TA 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy SG11202112980TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Publications (1)

Publication Number Publication Date
SG11202112980TA true SG11202112980TA (en) 2021-12-30

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112980TA SG11202112980TA (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Country Status (11)

Country Link
US (2) US20220388985A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986887A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537349A (cg-RX-API-DMAC7.html)
KR (1) KR102993656B1 (cg-RX-API-DMAC7.html)
CN (2) CN114206853A (cg-RX-API-DMAC7.html)
AU (1) AU2020296063B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142002A1 (cg-RX-API-DMAC7.html)
MA (1) MA56513A (cg-RX-API-DMAC7.html)
SG (1) SG11202112980TA (cg-RX-API-DMAC7.html)
WO (1) WO2020257416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
JP2024505228A (ja) * 2021-01-29 2024-02-05 ライボン・セラピューティクス・インコーポレイテッド 炎症性疾患を処置する方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN119923391A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN119923394A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
EP4119552A1 (en) * 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14

Also Published As

Publication number Publication date
CN114206853A (zh) 2022-03-18
JP2025102917A (ja) 2025-07-08
EP3986887A1 (en) 2022-04-27
WO2020257416A1 (en) 2020-12-24
BR112021025645A2 (pt) 2022-02-01
JP7844707B2 (ja) 2026-04-13
CN120398840A (zh) 2025-08-01
KR20220024098A (ko) 2022-03-03
CA3142002A1 (en) 2020-12-24
JP2022537349A (ja) 2022-08-25
AU2020296063A1 (en) 2021-12-23
AU2020296063B2 (en) 2026-01-29
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
KR102993656B1 (ko) 2026-07-23
US20220388985A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
IL276464A (en) Methods and preparations for administering therapeutic protein
IL287082A (en) Methods and preparations for targeted unloading of proteins
MA56513A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
ZA201803661B (en) Compositions and methods for decreasing tau expression
IL292810A (en) Therapeutic compounds and methods of use
ZA201804223B (en) Bromodomain and extra-terminal protein inhibitor combination therapy
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
SI3532059T1 (sl) Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom
IL288728A (en) Anti-sortilin antibodies for use in therapy
ZA202101587B (en) Protein for treatment of inflammatory diseases
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
EP3886913A4 (en) IMPROVED TARGETED DELIVERY OF THERAPEUTICS
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
ZA202106250B (en) Therapeutic uses of dulaglutide
IL318518A (en) Targeted protein degradation of PARP14 for use in therapy
HK40073749A (en) Targeted protein degradation of parp14 for use in therapy
IL318530A (en) Targeted protein degradation of PARP14 for use in therapy
GB201812861D0 (en) Methods of administering therapy
EP3579886A4 (en) METHOD OF USE FOR THERAPEUTIC BONE ASSOCIATION
HUE069517T2 (hu) Eljárás fexapotid-triflutát terápiás hatékonyságának fokozására LUTS kezelésében
HK40127147A (en) Targeted protein degradation of parp14 for use in therapy
HK40127146A (en) Targeted protein degradation of parp14 for use in therapy
AU2019903877A0 (en) Inhibitors of protein kinases for use in therapy
GB201913114D0 (en) Targeted sequencing of y-chromosome